Fox Run Management, L.L.C. Immunovant, Inc. Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$31.31 - $44.19 $455,059 - $642,257	14,534 New	14,534 $612,000
Q1 2023 May 12, 2023	BUY	$15.27 - $19.72 $1,557 - $2,011	102 Added 0.8%	12,882 $199,000
Q4 2022 Feb 07, 2023	BUY	$6.59 - $17.75 $84,220 - $226,845	12,780 New	12,780 $226,000
Q1 2022 May 10, 2022	SELL	$5.06 - $8.77 $54,663 - $94,742	-10,803 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$7.33 - $9.32 $22,788 - $28,975	-3,109 Reduced 22.35%	10,803 $92,000
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $97,523 - $158,179	13,912 New	13,912 $121,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.